Sarepta Faces Scrutiny After Second Gene Therapy Death
Reading
Sarepta had bad news about their gene therapy drug. The company's stock value went down a lot on Monday. This happened after a second death was reported with the treatment.
The company stopped sending the drug to some older patients. This is for patients who cannot walk anymore. The drug, Elevidys, treats a type of muscular dystrophy in children.
Elevidys is the first gene therapy for this muscle problem in the US. It got approved quickly in 2023, but had some problems. A second death was reported, like one before in March.
The second death was a boy who had liver problems. Older patients get a bigger dose of the medicine. Sarepta will stop a study with older patients and get expert advice.
The company will work with the FDA on any changes to the drug. Some FDA scientists had worries about the drug before. The company's stock fell a lot because of these problems.
Questions
What happened to Sarepta's stock value?
Sarepta's stock value went down a lot on Monday.
What is the name of the drug that Sarepta makes?
The drug is called Elevidys.
Why did Sarepta stop sending the drug to some older patients?
Sarepta stopped sending the drug to some older patients because of safety concerns after a second death was reported.
Describe the article image
Look at the article image and describe what you see on it. You may either speak or write your answer there.
Discussion
Discuss this article with your AI tutor to practice. Your tutor will help you with vocabulary and grammar.
Read a new article every day anddiscuss it with AI at lingolette.com